# TB-500 and Thymosin Beta-4 research — Mechanism, preclinical, clinical

> Mechanism, animal-study findings, registered human trials, and 2024–2025 combination delivery work for TB-500 and full-length Thymosin Beta-4. Sourced from peer-reviewed literature.

A peer-reviewed walk through actin biochemistry, the principal animal-study findings, every registered human trial, and the modern biomaterial direction.

## The short version

The TB-500 / Thymosin Beta-4 research record divides into three clear layers. The bulk of it is preclinical — rat and mouse studies showing accelerated wound closure [3], corneal healing [4], cardiac repair [6][7], stroke recovery [8][9], and muscle satellite-cell recruitment [12]. There is also a meaningful human dataset, but it belongs to full-length recombinant Tβ4, not the seven-amino-acid TB-500 fragment: three published Phase I safety studies and two clinical ophthalmic programmes [13][14][15][25]. And there is a regulatory layer: TB-500 sits on the FDA 503A compounding nomination docket with a PCAC review scheduled for July 2026, and it is WADA-prohibited under S2 and S0 [16][26].

The recurring editorial point is the fragment-versus-parent gap. TB-500 preserves the LKKTET actin-binding motif but not the downstream signalling surface that underpins most of the encouraging biology. Every section below flags which molecule a given finding actually studied.

## Mechanism: actin sequestration and the LKKTET motif

The molecular biology is unusually clean. Thymosin Beta-4 binds a single G-actin monomer in a 1:1 stoichiometric complex via its central LKKTET motif and surrounding C-terminal α-helix. Cassimeris and colleagues showed this directly in rabbit skeletal muscle and human platelet actin assays in 1992, establishing Tβ4 as the principal actin-sequestering peptide of resting platelets [1]. Irobi and colleagues solved the X-ray crystal structure of the complex in 2004, defining the C-terminal α-helix and the LKKTET central motif as the structural basis of G-actin sequestration and showing that the bound Tβ4 sterically blocks both barbed-end and pointed-end filament addition [2].

The LKKTET-bearing segment is the entire actin-binding warhead. The seven-amino-acid TB-500 synthetic preserves this motif intact, which is the biochemical case for the fragment retaining the parent's actin-sequestering activity. What the fragment does not preserve — and what is repeatedly under-acknowledged in vendor copy — is most of the parent protein's downstream interaction surface [25].

Full-length Tβ4 forms a regulatory complex with PINCH-1 and Integrin-Linked Kinase that activates Akt; it induces VEGF and Notch-mediated angiogenesis in endothelium; it directly binds NF-κB RelA/p65 to suppress TNF-α-driven IL-8 transcription [10]; and it is enzymatically cleaved by the Meprin-α → Prolyl Oligopeptidase axis to release the anti-fibrotic tetrapeptide Ac-SDKP. These activities are documented for the full protein. The published mechanistic and clinical efficacy data are dominated by the parent peptide, not the fragment.

## Preclinical evidence: dermal, corneal, cardiac, neural

**Dermal wound healing.** Malinda and colleagues showed in 1999 that topical or intraperitoneal Tβ4 at 5 μg per wound in 50 μL PBS accelerated re-epithelialisation of 8 mm full-thickness rat punch wounds by 42% at day 4 and up to 61% at day 7, with increased angiogenesis and faster collagen deposition [3]. Philp and colleagues extended this in 2003 to db/db diabetic mice and aged mice, and — importantly for the fragment question — explicitly showed that a synthetic peptide containing only the actin-binding domain promoted dermal wound repair in those impaired-healing models [5].

**Corneal repair.** Sosne and colleagues established the keystone preclinical evidence underwriting the entire RGN-259 ophthalmic clinical programme in 2002: topical Tβ4 at 5 μg in 5 μL PBS twice daily accelerated corneal re-epithelialisation at every measured time point and significantly reduced IL-1β, KC, and MIP-2 inflammatory mRNA after alkali burn in 129 Sv mice [4].

**Cardiac repair.** Bock-Marquette and colleagues published the seminal cardiac result in Nature in 2004: after coronary artery ligation in mice, Tβ4 upregulated cardiac ILK and Akt, enhanced cardiomyocyte survival, reduced scar size, and improved fractional shortening at four weeks [6]. Smart and colleagues followed in Nature in 2007 by showing that 150 μg Tβ4 intraperitoneally every three days mobilised adult epicardial progenitor cells in mice, restored their multipotent capacity, and drove neovascularisation in the injured adult heart [7]. The negative companion result is in Wei 2016: systemic Tβ4 dosing at 150 μg/kg IV bolus plus maintenance in a closed-chest porcine 90-minute ischaemia / 24-hour reperfusion model failed to attenuate global myocardial infarct size by either TTC staining or cardiac MRI [17]. The rodent-to-large-mammal translational gap is documented in the same body of work that establishes the rodent benefit.

**Neural recovery.** Morris and colleagues showed in 2010 that intravenous Tβ4 at 3.75 mg/kg administered 24 hours after embolic middle-cerebral-artery occlusion in rats improved adhesive-removal performance and modified Neurological Severity Scores from day 14 through day 56 post-stroke [8]. A dose-response follow-up in 2014 confirmed 3.75 mg/kg IV as the optimum across a 0.5–36 mg/kg single-dose range, with a non-monotonic dose-response curve and sustained benefit at the optimum out to day 56 [9].

**Hair follicle and skeletal muscle.** Philp and colleagues documented Tβ4 activation of hair-follicle stem cells in rat vibrissa follicle and mouse skin models [11]. Tokura and colleagues showed in 2011 that Tβ4 acts as a chemoattractant for satellite-cell-derived myoblasts after skeletal muscle injury in mouse cardiotoxin and freeze-injury models [12].

**Endothelial signalling.** Ho and colleagues defined the principal endothelial pathway downstream of Tβ4 in 2013: in HUVEC, recombinant Tβ4 at 10–500 ng/mL induced angiogenesis through a Notch1 / Notch4 / VEGF / HIF-1α cascade, with Notch inhibition abolishing the Tβ4-driven VEGF and HIF-1α response [13].

## Clinical evidence: five published human datasets

Every registered, peer-reviewed human clinical trial of "thymosin beta-4" has used the full-length 43-amino-acid recombinant peptide, not the synthetic seven-amino-acid TB-500 heptapeptide. The disambiguation matters when reading the trial numbers below.

**RGN-259 Phase III neurotrophic keratopathy (NCT02600429, n=18).** A randomised, placebo-controlled, double-masked Phase III trial of 0.1% Tβ4 ophthalmic solution dosed six times per day for 28 days produced complete corneal healing at day 29 in 60% of treated subjects versus 12.5% of placebo (p=0.066, narrow miss on the prespecified primary endpoint) and statistically significant healing at day 43 (p=0.036), with sustained benefit after washout [15]. This is the most-cited recent human efficacy result for the molecule.

**RGN-259 Phase III dry eye (ARISE-1/2/3).** The dry eye programme missed prespecified primary endpoints but produced positive secondary signals on ocular grittiness and two-week central corneal staining. The narrative review of the programme attributed part of the primary endpoint miss to high placebo response [22]. A planned 46-subject SEER expansion in neurotrophic keratitis was terminated early due to slow rare-disease recruitment.

**RGN-352 Phase II post-acute-MI cardiac repair.** Intravenous full-length Tβ4 at 450 mg or 1,200 mg daily for three days then weekly for four weeks in approximately 75 patients [25].

**Ruff 2010 — US Phase I IV safety.** A randomised, double-blind, single- and multiple-dose study of intravenous recombinant Tβ4 in 40 healthy adult volunteers, single doses of 42, 140, 420, and 1,260 mg with a multiple-dose extension, established acceptable safety and tolerability with no dose-limiting toxicities and no serious adverse events [13].

**Wang 2021 — Chinese Phase I IV safety.** A first-in-human Chinese Phase I trial of recombinant Tβ4 (NL005) in 84 healthy volunteers, single doses 0.05–25 μg/kg IV and multiple doses 0.5–5 μg/kg/day IV for 10 days, confirmed dose-linear PK with no accumulation, no SAEs, and no dose-limiting toxicities [14].

Three human safety datasets, two human efficacy programmes, no Phase III primary endpoint hit. That is the published clinical record at the time of writing. No registered human efficacy or pharmacokinetic study of the synthetic seven-amino-acid TB-500 fragment has been published in the peer-reviewed literature [25].

## Anti-inflammatory and context-dependent biology

Qiu and colleagues showed in 2011 that Tβ4 directly binds NF-κB RelA/p65, blocking TNF-α-driven NF-κB activation and downstream IL-8 transcription in human HCT116 and HeLa cells, with PINCH-1 and ILK acting as sensitisers [10]. The mechanism is independent of G-actin binding — molecular evidence that Tβ4's anti-inflammatory activity is not a side-effect of its cytoskeletal role.

The biology is also context-dependent. Lee and colleagues showed in 2023 that conditional deletion of Tβ4 in activated hepatic stellate cells in a transgenic mouse model (Tβ4-flox × αSMA-Cre-ERT2) attenuated CCl4- and bile-duct-ligation-induced liver fibrosis by repressing Hedgehog signalling [19]. Tβ4 accelerates dermal, corneal, and cardiac repair in rodents but appears pro-fibrotic in hepatic stellate cells. Indiscriminate systemic dosing across organ systems is not biologically neutral, and the simple "Tβ4 is anti-fibrotic" narrative does not survive the published evidence.

## Modern direction: biomaterial and exosome delivery

The 2024–2025 Tβ4 research direction is combination delivery rather than free peptide. Yu and colleagues showed in 2025 that Tβ4-overexpressing adipose-stem-cell exosomes loaded into a HAMA/PLMA dual-photopolymerisable hydrogel accelerated diabetic wound closure in streptozotocin-induced type-1 diabetic C57BL/6 mice by stimulating angiogenesis, collagen synthesis, and macrophage polarisation via PI3K/AKT/mTOR/HIF-1α [20]. Yang and colleagues published an engineered tandem-repeat Tβ4 construct (tTB4) in 2024 with two G-actin-binding domains fused into a single polypeptide, which promoted corneal epithelial migration in hTCEpi cells and produced thicker, more continuous epithelium in vivo than monomeric Tβ4 [21]. Engineered LKKTET-containing constructs — the class TB-500 belongs to — can amplify the corneal-healing activity of the parent peptide.

Xing and colleagues catalogued the modern Tβ4 record across angiogenesis, anti-inflammation, anti-apoptosis, anti-fibrosis, and progenitor mobilisation in a 2021 Frontiers in Endocrinology review [24]. Goldstein and colleagues catalogued the same field in 2012 and were explicit about the evidence gap that this site treats as its headline editorial point: "Tβ4" in animal studies almost always refers to the full 43-amino-acid peptide, and strict comparison studies between full Tβ4 and its shorter LKKTET-containing fragments remain sparse [25].

---

An independent editorial console for the peer-reviewed record — not a clinic, not a vendor, not medical advice.